It looks like you're new here. If you want to get involved, click one of these buttons!
div>Two patients in whom previous surgical annuloplasty failed to maintain MR reduction and who were treated with the MitraClip device after mitral valve Bay 11-7085 repair surgery are described. Imaging and hemodynamic considerations associated with this approach are discussed. ? 2010 Wiley-Liss, Inc. ""We sought to determine the contemporary prevalence and management of coronary chronic total occlusions (CTO) in a veteran population. The prevalence and management of CTOs in various populations has received limited study. We collected clinical and angiographic data in consecutive patients that underwent coronary angiography at our institution between January 2011 and December 2012. Coronary artery disease (CAD) was defined as ��50% diameter stenosis in ��1 coronary artery. CTO was defined as total coronary artery occlusion http://www.selleckchem.com/products/KU-60019.html of ��3 month duration. Among 1,699 patients who underwent angiography during the study period, 20% did not have CAD, 20% had CAD and prior coronary artery bypass graft surgery (CABG), and 60% had CAD but no prior CABG. The prevalence of CTO among CAD patients with and without prior CABG was 89 and 31%, respectively. Compared to patients without CTO, CTO patients had more co-morbidities, more extensive CAD and were more frequently referred for CABG. Percutaneous coronary intervention (PCI) to any vessel was performed with similar frequency in patients with and without CTO (50% vs. 53%). CTO PCI was performed in 30% of patients without and 15% of patients with prior CABG with high technical (82 and 75%, respectively) and procedural success rates (80 and 73%, respectively). In a contemporary veteran population, coronary CTOs are highly prevalent and are associated with more extensive co-morbidities and higher likelihood for CABG referral. PCI was equally likely to be performed in patients with and without CTO. ? 2013 Wiley Periodicals, Inc. ""To assess the impact of age on safety and efficacy of paclitaxel-eluting stent (PES) implantation during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). The benefits Doramapimod datasheet of paclitaxel-eluting stent (PES) implantation during primary PCI were confirmed by the long-term results of the HORIZONS-AMI trial. Whether the effects of PES are independent of age has not been reported. Data on 3,006 patients from the HORIZONS-AMI study randomized in a 3:1 ratio to PES or bare-metal stent (BMS) in whom at least one stent was implanted were assessed. There were 2,302 (76.6%) patients <70, and 704 patients ��70 years of age. At 3 years, among older patients a trend toward lower risk of major adverse cardiac events (MACE; death from any cause, stroke, reinfarction and unplanned revascularization for ischemia) related to PES use was observed (PES vs. BMS: 18.0% vs. 21.3%; P?=?0.07). There was also a trend for reduction of MACE related to PES in older patients (26.4% vs. 33.1%; P?=?0.09).